Could a gut bacteria transplant ease a rare lung disease?
NCT ID NCT07751120
First seen Aug 07, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This early-stage trial tests whether transplanting gut bacteria from healthy donors, along with antibiotics and fiber, is safe and feasible for people with pulmonary arterial hypertension (PAH), a condition of high blood pressure in the lungs. About 24 adults with PAH will be randomly assigned to receive the bacteria capsules with fiber, bacteria with a placebo, or placebos only. Researchers will track how well the donor bacteria take hold in the gut, monitor side effects, and look at early signs of impact on heart function, walking ability, and quality of life.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Microbiota transplant therapy (freeze-dried gut bacteria from healthy donors) with antibiotic preconditioning and fiber supplementation
- What this could lead to
- If successful, this could pave the way for a new gut-based treatment for pulmonary arterial hypertension, potentially improving symptoms and quality of life.
- What could go wrong
- This is an early, small pilot study focused on safety and feasibility, not proof of effectiveness. The transplant may not engraft or provide clinical benefit, and there are risks from antibiotics and the transplant itself.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Minnesota
Minneapolis, Minnesota, 55414, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new pill ease the strain of pulmonary arterial hypertension?
- Can a diabetes drug help the heart burn fuel better in pulmonary hypertension?
- Can a smartwatch replace the clinic walk test for lung disease patients?
- Blood particles may reveal hidden clues to scleroderma complications
- Heart scans may soon replace Needle-Based catheter tests
- Could a new drug free PAH patients from daily pump therapy?